Reactive Arthritis ResearchAntiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis.Primary Author: E BressanPrimary Author: Department of Pharmacology, CCB, Federal University of Santa Catarina, Campus Trindade, Florianópolis, SC, 88040-900, Brazil.Date Published: 2008 12 25Abstract: OBJECTIVE: Nonsteroidal anti-inflammatory drugs constitute the primary therapeutic approach in reactive arthritis. Here, we compared etoricoxib, a specific COX-2 inhibitor, with other cyclooxygenase inhibitors on articular incapacitation, edema, leukocyte migration, and gastric damage, in a model of LPS-induced reactive arthritis in rats.METHODS: E. coli Lipopolysaccharide was injected into a carrageenan-primed knee-joint of rats. The effects of etoricoxib, piroxicam, indomethacin, as well the combination of etoricoxib either with piroxicam or indomethacin, were evaluated on articular incapacitation and edema. Afterwards, the synovial leukocyte ontent and the stomach bleeding points were counted.RESULTS: Etoricoxib, piroxicam, and indomethacin dose-dependently inhibited incapacitation and edema. However, only etoricoxib inhibited both mononuclear and polymorphonuclear leukocyte migration. Piroxicam inhibited only mononuclear migration, while indomethacin even increased polymorphonuclear content in inflamed synovia. Associating etoricoxib with either subeffective doses of piroxicam or indomethacin did not enhance the hyponociceptive or the antiedematogenic effect, but prevented the anti-leukocyte migration effect and increased gastric damage.CONCLUSION: The present results suggest that the selective COX-2 inhibitor etoricoxib could be a better option than non-selective COX inhibitors, since it presented a potent inhibitory effect on the clinical signals and also a potent inhibition on cell migration.
Erosive arthritis in systemic lupus erythematosus is associated with high serum C-reactive protein and anti-cyclic citrullinated peptide antibodies.Primary Author: L M Amezcua-GuerraPrimary Author: Department of Immunology, Instituto Nacional de Cardiología Ignacio Chavez, Juan Badiano 1, Sección XVI, Tlalpan, 14080, Mexico City, Mexico.Date Published: 2008 12 25Abstract: Predictors for erosive arthritis in systemic lupus erythematosus (SLE) are poorly understood. We performed a pilot, descriptive case-series study to identify whether different biomarkers differentiate SLE patients from those additionally developing erosive arthritis. Median C-reactive protein (CRP) concentration in erosive arthritis was 14.5 mg/L (IQR, 6.6-19.4), but only 0.8 (0.45-7.37, p = 0.01) in non-erosive. Anti-cyclic citrullinated peptide antibodies (anti- CCP) were also associated with erosive arthritis (60 vs. 0% , p = 0.02; OR = 18.2, 0.66-495). Serum IL-6, IFNgamma, IL-4 and IL-10 tended to be higher in erosive arthritis, although none attained statistical significance. A negative correlation between IL-6 and CRP was found in non-erosive arthritis ( r-0.60). High CRP and anti-CCP may be useful serological markers for an erosive arthritis pattern among SLE patients.
|
Common Types of Arthritis
Arthritis Treatments Home |
